Joe Tippens Cancer Patient
Tippens’ older brother Tom said when he was on the immunotherapy drug, Tippens was “literally walking death.”
“He was down to 115-120 pounds — he had no energy, he was just dried out,” Tom said.
Days later, Joe called family friend David Sturgeon, a large animal veterinarian, after reading a post on an Oklahoma State University sports board. Sturgeon informed Tippens about an unnamed scientist at Merck Animal Health who was conducting research on cancerous mice by injecting them with , a canine deworming product line.
The scientist ended up being diagnosed with glioblastoma, a type of brain cancer, herself and decided to take the . She cured her cancer six weeks after taking it.
Humphrey, H. (2019, November 12). The canine medication that beat small cell lung cancer. UCentral Media. *https://ucentralmedia.com/the-canine-medication-that-beat-small-cell-lung-cancer/
There is considerable information online about this individual, including forums and videos. For specific details, search for his name online.
In 2016, Joe Tippens was diagnosed with small-cell lung cancer, an aggressive form of the disease. By the time of diagnosis, the cancer had spread to other parts of his body, including his liver and bones. Tippens was given a prognosis of several months to live. He started standard treatments and also investigated non-standard or unapproved methods. His search included fenbendazole, a compound used in veterinary antiparasitic products. His doctors did not recommend its use. Tippens began self-administering fenbendazole along with other supplements such as CBD oil and curcumin. He documented his experience. After several months, scans indicated changes in his tumors, which decreased in size and appeared inactive. His cancer was reported to be in remission. During this period, he was also enrolled in a drug trial and received other conventional medications. As of 2025, Tippens is reported to be alive and healthy. He attributes his remission to fenbendazole and discusses its use in humans.
After being diagnosed with cancer, many sick patients and their caregivers are wiped out by the financial and emotional toll of the disease and treatment options. After Joe Tippens’ story about fenbendazole became public, a wave of positive news spread around the world. The idea that cancer could be slowed or stopped by a cheap, readily available drug already in use for decades brought hope to many sick people.
Tippens was also a participant in a clinical trial at MD Anderson involving the immunotherapy drug Keytruda.
While on the Keytruda trial, he[Tippens] also began self-administering fenbendazole with other supplements. His subsequent remission was widely publicized as a “fenbendazole miracle,” but medical experts suggest his positive outcome was likely due to the immunotherapy trial rather than the unproven animal drug. MD Anderson does not support the use of fenbendazole for human cancer treatment.
Figure it out for yourself: was it fenbendazole or the trial?